- Home
- KLRS vs CEV Comparison
KLRS vs CEV Comparison
Compare KLRS & CEV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KLRS
- CEV
- Stock Information
- Founded
- KLRS 2019
- CEV 1999
- Country
- KLRS United States
- CEV United States
- Employees
- KLRS N/A
- CEV N/A
- Industry
- KLRS Biotechnology: Biological Products (No Diagnostic Substances)
- CEV Finance/Investors Services
- Sector
- KLRS Health Care
- CEV Finance
- Exchange
- KLRS Nasdaq
- CEV Nasdaq
- Market Cap
- KLRS 129.0M
- CEV 67.8M
- IPO Year
- KLRS N/A
- CEV N/A
- Fundamental
- Price
- KLRS $3.89
- CEV $9.84
- Analyst Decision
- KLRS Buy
- CEV
- Analyst Count
- KLRS 1
- CEV 0
- Target Price
- KLRS N/A
- CEV N/A
- AVG Volume (30 Days)
- KLRS 62.9K
- CEV 19.6K
- Earning Date
- KLRS 05-19-2025
- CEV 01-01-0001
- Dividend Yield
- KLRS N/A
- CEV 4.23%
- EPS Growth
- KLRS N/A
- CEV N/A
- EPS
- KLRS N/A
- CEV 0.36
- Revenue
- KLRS N/A
- CEV N/A
- Revenue This Year
- KLRS N/A
- CEV N/A
- Revenue Next Year
- KLRS N/A
- CEV N/A
- P/E Ratio
- KLRS N/A
- CEV $29.36
- Revenue Growth
- KLRS N/A
- CEV N/A
- 52 Week Low
- KLRS $4.19
- CEV $8.83
- 52 Week High
- KLRS $24.15
- CEV $10.91
- Technical
- Relative Strength Index (RSI)
- KLRS N/A
- CEV 51.08
- Support Level
- KLRS N/A
- CEV $9.74
- Resistance Level
- KLRS N/A
- CEV $9.86
- Average True Range (ATR)
- KLRS 0.00
- CEV 0.08
- MACD
- KLRS 0.00
- CEV 0.03
- Stochastic Oscillator
- KLRS 0.00
- CEV 78.95
About KLRS Kalaris Therapeutics Inc. Common Stock
Kalaris Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing therapeutics. Kalaris is developing TH103, a novel, clinical stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body native, highest affinity VEGF receptor 1.
About CEV Eaton Vance California Municipal Income Trust Shares of Beneficial Interest
Eaton Vance CA Muni Income Trust is a non-diversified closed-end investment company. The company's investment objective is to provide current income exempt from regular federal income tax and California state personal income taxes. It invests in municipal obligations, issued by the State of California or its political subdivisions, agencies, authorities and instrumentalities and also has some exposure to corporate bonds.